Le Lézard
Classified in: Health
Subjects: FDA, PLW

FDA Clears Xavant Technology's Stimpod NMS460 Non-Invasive Neuromodulation Device for Treatment of Chronic Intractable Pain



PRETORIA, South Africa, Aug. 1, 2017 /PRNewswire/ -- Xavant Technology (Pty) Ltd today announced that the U.S. Food and Drug Administration (FDA) cleared their Stimpod NMS460. With the U.S. patent awarded on proprietary hybrid pulsed radio frequency (PRF) waveform, this non-invasive neuromodulation device is focused on the symptomatic relief and management of chronic intractable pain, as well as an adjunctive treatment in the management of post-surgical pain, post-traumatic acute pain problems, and an adjunct for pain control due to rehabilitation.

The need for this device is profound. More than 100 million Americans report that they have a problem with pain.[1] Chronic pain is characterized by neuroplastic changes that cause sensitization of the nervous system. These changes result in anatomical and physiological changes that affect neurological function, which causes long-term potentiation and gene expression changes that then allow the pain to continue with or without further peripheral input, and a lower pain threshold; this dysfunction then also accounts for the epiphenomena associated with the disease, including emotional, memory, and motor changes, which then becomes the illness of chronic pain.[2]

Treatment of chronic pain in the United States is estimated to cost $600 billion annually.[3] The current standard of care for chronic pain includes drug cocktails such as Corticosteroids, Opiate pain relievers, injections, and beyond combined with treatments like physical therapy and counseling. Treatments can come with various short-term and long-term side effects.

The Stimpod NMS460, however, will greatly impact the industry as a non-invasive, non-drug solution with zero side effects and a fast onset of effect at a fraction of the cost of comparable treatments. The device applies its patented PRF waveform to the affected area transcutaneously. This waveform creates electromagnetic effects similar to invasive pulsed radio frequency treatments, and several case studies have shown instant and dramatic relief of chronic intractable pain. The Stimpod NMS460 also incorporates the nerve-locating technology which features a nerve mapping probe that enables practitioners to locate nerves and evaluate the treatment progress of damaged nerves. Bell Medical has been selected as the master distributor for both the U.S. and Canada.

"We are thrilled at the news that our revolutionary device can now be used in the U.S.," said Corlius Birkill, CEO of Xavant Technology (Pty) Ltd. "This groundbreaking technology has the ability to help tens if not hundreds of millions of people just in the U.S. as a valuable treatment asset for neurologists, chiropractors, acupuncturists, physical therapists, physiatrists, and medical pain practitioners."

About Xavant Technology (Pty) Ltd
Xavant Technology (Pty) Ltd is a leading supplier of nerve stimulators for regional and general anesthesia applications. The current Stimpod range has three models - the NMS410, NMS450 and NMS460. The Stimpod NMS460 is a neuromodulation device used for symptomatic relief of chronic intractable pain, implementing a unique patented Pulsed Radio Frequency waveform for the treatment of neuropathies. The Stimpod NMS410 model is a specialized nerve locating device, with its unique nerve mapping and locating cable, used primarily during Regional Anesthesia procedures. The Stimpod NMS450 adds the option to monitor neuromuscular blocking agents with its advanced three-dimensional accelerometer. Learn More About STIMPODNMS460 at http://www.stimpodnms460.com.

Media Contact: 
Lourie Höll
Phone: +27 12 743 5959 
Email: media@xavant.com

[1] Gaskin, Darrell J., and Patrick Richard. "The Economic Costs of Pain in the United States." The Journal of Pain: Official Journal of the American Pain Society (2012): 715-24. Web. 21 June 2017.

[2] American Academy Of Pain Medicine. Neuropathic Pain Recognized as a Disease. N.p.: American Medical Association, 27 Sept. 2016. PDF. https://assets.ama-assn.org/sub/meeting/documents/i16-resolution-912.pdf

[3] Gaskin, Darrell J., and Patrick Richard. "The Economic Costs of Pain in the United States." The Journal of Pain: Official Journal of the American Pain Society (2012): 715-24. Web. 21 June 2017.

Related Images

image1.png

image2.jpg

image3.jpg

image4.jpg

Related Links

Stimpod NMS460 website

Related Video

http://www.youtube.com/watch?v=CjaJ3_BTRcw

SOURCE Xavant Technology (Pty) Ltd


These press releases may also interest you

at 04:00
WASHINGTON, Oct. 19, 2017 /PRNewswire/ -- According to The International Trade Association, the global medical device, technology and equipment market is growing from $360 B to $450 B in 2018. While there's tremendous opportunity for startups and...

at 04:00
DURHAM, North Carolina, Oct. 19, 2017 /PRNewswire/ -- Alcami Corporation, a leading provider of custom development and manufacturing services for the pharmaceutical and biotechnology industries, today announces the launch of its international...

at 04:00
ZURICH, October 19, 2017 /PRNewswire/ -- Sequana Medical AG (Sequana Medical), a commercial stage medical device company and an innovator in the management of liver disease, today announced that it will have a poster presentation at the upcoming...

at 04:00
TraceLink, Sharp and Major Pharma Brand to Discuss Trade Partner Connectivity at CPhI Worldwide NORTH READING, Massachusetts, Oct. 19, 2017 /PRNewswire/ -- TraceLink Inc., the World's Largest Track and Trace Network for connecting the life...

at 03:00
LUGANO, Switzerland, October 19, 2017 /PRNewswire/ -- ESMO, the leading professional organisation for medical oncology, has granted the newly established ESMO Award for Immuno-Oncology to Prof Laurence Zitvogel for her innovating and internationally...

at 02:16
UPPSALA, Sweden, Oct.19, 2017 /PRNewswire/ -- Financial overview Q3 2017 Total net revenues SEK 166.2 million (181.9) Zubsolv® US net revenue SEK 121.1 million (142.4) EBIT SEK 40.9 million (43.0) EBITDA SEK 46.1 million (50.9) Earnings per...




News published on 1 august 2017 at 13:00 and distributed by: